Stephanie O'Brien - Jan 1, 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Stephanie O'Brien
Stock symbol
APLS
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 04:33 PM
Previous filing
Jan 4, 2022
Next filing
Jan 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +3.87K +91.42% $0.00 8.1K Jan 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $0 +7.44K $0.00 7.44K Jan 1, 2023 Common Stock 7.44K $51.71 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This restricted stock unit was granted on January 1, 2023. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to her continued service as a director, or upon later termination of her service as a director at her election.
F2 This option was granted on January 1, 2023. The option vests quarterly on the last day of each quarter from the date of grant, subject to her continued service as a director and expires seven years after the date of grant.